Can UCB sustain its Q1 2025 EPS growth?

**UCB's Q1 2025 EPS growth appears sustainable based on several key factors**: 1. **Consistent Growth Trajectory**: UCB has demonstrated a strong growth trajectory in recent years, with a reported increase in revenue and net sales in 2024. This consistent growth indicates a robust business model that can support continued EPS growth. 2. **Positive Earnings Outlook**: Analysts covering UCB have mostly recommended stock overweighting or purchase, and the average price target has been revised upwards significantly. This positive sentiment suggests confidence in UCB's future earnings potential, including the Q1 2025 period. 3. **Strong Fundamentals**: UCB's strong fundamentals, such as high profit margins and a robust financial situation, provide a solid foundation for sustaining EPS growth. The company's net charge-offs have been low, indicating stable credit quality, which is a positive indicator for financial performance. 4. **Innovative Pipeline**: UCB's ongoing innovation in drug development and recent approvals in key markets position the company well for continued growth. The company is studying 9 innovative potential medicines with expected news flow in 2025, which could contribute to future EPS growth. 5. **Strategic Partnerships**: UCB's strategic partnerships, such as the partnership with Powin to accelerate Brazil's utility-scale energy storage market, could open up new revenue streams and support EPS growth. In conclusion, UCB's strong financial performance, positive earnings outlook, innovative pipeline, and strategic partnerships suggest that the company's Q1 2025 EPS growth is likely to be sustainable.